2016
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therapeutic Advances In Gastroenterology 2016, 9: 560-579. PMID: 27366224, PMCID: PMC4913338, DOI: 10.1177/1756283x16644247.Peer-Reviewed Original ResearchDNA methyltransferaseEpigenetic dysregulationEpigenetic drugsEpigenetic therapyCpG island methylator phenotypeDeoxyribonucleic acid methylationChromatin remodelingHistone modificationsCancer epigenomeEpigenetic reprogrammingWidespread epigenetic dysregulationCancer epigeneticsEpigenetic targetsCancer stem cellsHistone deacetylase inhibitorsMolecular biologyAcid methylationStem cellsDeacetylase inhibitorsDevelopment of drugsEpigeneticsGenetic mutationsMethylator phenotypeChemo resistanceEpigenetic sensitization
2015
Epigenetic therapy for solid tumors: from bench science to clinical trials
Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 2015, 7: 215-235. PMID: 25942532, DOI: 10.2217/epi.14.73.Peer-Reviewed Original ResearchConceptsEpigenetic agentsCpG island promotersSolid tumorsGlobal DNA methylationOptimal patient selectionTumor suppressor geneNew therapeutic modalitiesChromatin changesCancer epigenomeHistone deacetylase inhibitorsDNA methylationDNA methyltransferaseEpigenetic therapyHormonal therapyDrug regimenSuppressor genePatient selectionFuture trialsHematologic malignanciesRecent trialsClinical trialsSignificant efficacyTherapeutic modalitiesPhenotype changesDeacetylase inhibitors